FOLFOXIRI + bevacizumab versus FOLFOX + panitumumab for metastatic left sided RAS/BRAF wild type colorectal cancer: Which "side" are you on?

FOLFOXIRI + bevacizumab versus FOLFOX + panitumumab for metastatic left sided RAS/BRAF wild type colorectal cancer: Which "side" are you on?
Oncologist. 2021 Feb 04;:
Authors: Yu IS, Loree JM
Abstract
This commentary focuses on the results of Pietrantonio et al.'s recent manuscript evaluating the clinical conundrum of triplet versus doublet chemotherapy in combination with targeted therapy for metastatic left sided RAS/BRAF wild type colorectal cancer. Both FOLFOXIRI + bevacizumab and FOLFOX + panitumumab have shown impressive activity in this population, however the two have not been directly compared. The study accompanying this commentary presents a propensity score adjusted analysis using information from five previous randomized trials and provides best available evidence comparing these regimens. We will discuss their findings and how they fit in current treatment paradigms.
PMID: 33539032 [PubMed - as supplied by publisher]

Source: The Oncologist - February 4, 2021 Category: Cancer & Oncology Authors: Yu IS, Loree JM Tags: Oncologist Source Type: research